Intraoperative use of recombinant activated factor VII (rFVIIa)

Minerva Anestesiologica

Volumn 72, Issue 6, 2006, Pages 489-494

  De Gasperi, Andrea ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Bleeding; Procoagulant factors; Recombinant factor VII

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ABDOMINAL SURGERY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG INDICATION; DRUG TREATMENT FAILURE; GLANZMANN DISEASE; HEMOPHILIA; HEMOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; LIVER SURGERY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR SURGERY; OBSTETRIC OPERATION; POSTOPERATIVE HEMORRHAGE; REVIEW; SURVIVAL RATE; THROMBOCYTE DISORDER; THROMBOCYTE TRANSFUSION; THROMBOSIS; TRAUMATOLOGY;

BLOOD LOSS, SURGICAL; FACTOR VIIA; HUMANS; INTRAOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 33745233313     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Hedner U, Erhardtsen E. Potential role for recombinant FVIIa in transfusion medicine. Transfusion 2002;42:114-24.
2. Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma. Semin Hematol 2004;41:55-64.
3. Goodnough LT, Lublin DM, Zhang L, Despostis G, Eby C. Transfusion medicine service policies for recombinant FVIIa administration. Transfusion 2004;44:1325-31.
4. Grounds RM, Bolan C. Clinical experiences and current evidence for therapeutic recombinant FVIIa treatment in nontrauma settings. Crit Care 2005;9:S36-45.
5. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis. Anesthesiology 2004;100:722-30.
6. Levi M. Critical bleeding in surgery: conventional therapy and new perspectives. Minerva Anestesiol 2004;70:267-71.
7. Menzebach A, Cassens U, Van Aken H, Booke M. Strategies to reduce perioperative blood loss related to non surgical bleeding. Eur J Anaesthesiol 2003;20:764-70.
8. Williams AP, Gettinger A. Transfusion therapy in the ICU. Curr Opin Anesthesiol 2006;19:127-31.
9. O'Connel NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIA in the management of uncontrolled hemorrhage. Transfusion 2003;43:1711-6.
10. Hendricks HGD, Mejer K, De Wolf JT, Klompaker IJ, Porte R, de Camp PJ et al. Reduced transfusion requirements by recombinant Factor VII a in orthotopic liver transplantation. Transplantation 2001;71:402-5.
11. De Gasperi A, Baudo F, DeCarlis L. Recombinant Factor VIIa in orthotopic liver transplantation: a preliminary single center experience. Intensive Care Med 2005;31:315-6.
12. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double blind placebo controlled randomized trial. Lancet 2003;361:201-5
13. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D et al. Recombinant coagulation FVIIa in major liver resection: a randomized placebo controlled double blind clinical trial. Anesthesiology 2005;102:269-75.
14. Planinsic RM, van der Meer J, Testa G, Grande L, Candela A, Porte RJ et al. Safety and efficacy of a single bolus administration of rFVIIa in liver transplantation. Liver Transpl 2005;11:895-900.
15. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of rFVIIa in trauma. Crit Care 2005;9:S15-24.
16. Spence RK, Martinez A. Coagulation in trauma. Dilution and massive transfusion. In: Spiess BD, Spence RK, Shander A editors. Perioperative transfusion medicine. Philadelphia: Lippincott; 2006. p. 329-36.
17. Levi M, Peters M, Buller HR. Efficacy and safety of rFVIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005;33:883-90.
18. Surudo T, Wojcicki M, Mikievicz P, Czuprynska M, Lubikowski J, Jarosz K et al. Rapid correction of prothrombin time after low dose rFVIIa in patients undergoing orthotopic liver transplantation. Transpl Proc 2003;35:2323-5.
19. Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S et al. Efficacy and safety of repeated perioperative doses of r FVIIa in liver transplantation. Liver Transpl 2005;11:973-9.
20. Porte RJ, Caldwell SH. The role of recombinant factor VIIa in liver transplantation. Liver Transpl 2005;11:872-4.
21. Shao YF, Yang JM, Chao GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E et al. Safety and hemostatic effects of rFVIIa in cirrhotic patients undergoing partial hepatectomy: a multicenter randomized double blind placebo controlled trial. Am J Surg 2006;191:245-9.
22. De Gasperi A, Baudo F. Use of rFVIIa during orthotopic liver transplantation. Liver Transpl 2006. In press.
23. De Gasperi A, Amici O, Mazza E, Garrone, F, Sciascia A, Corti A. Monitoring intraoperative coagulation. Transpl Proc 2006. In press.
24. Stein DM, Dutton RP, O'Connor J, Alexandre M, Scalea TM. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma 2005;59:609-15.
25. Key NS. Recombinant FVIIa for intractable hemorrhage: more questions than answers. Transfusion 2003;43:1649-51.